This is not the most recent version of the article. View current version (6 AUG 2013)

Intervention Protocol

You have free access to this content

Laquinimod for multiple sclerosis

  1. Dian He1,
  2. Kai Han2,
  3. Xiangdong Gao3,
  4. Shuai Dong3,
  5. Lan Chu1,*,
  6. ZhanHui Feng1,
  7. Shan Wu1

Editorial Group: Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group

Published Online: 30 APR 2013

DOI: 10.1002/14651858.CD010475


How to Cite

He D, Han K, Gao X, Dong S, Chu L, Feng Z, Wu S. Laquinimod for multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD010475. DOI: 10.1002/14651858.CD010475.

Author Information

  1. 1

    Affiliated Hospital of Guiyang Medical College, Department of Neurology, Guiyang, Guizhou Province, China

  2. 2

    Jinan No. 6 People's Hospital, Electrophysiology Center, Jinan, Shandong Province, China

  3. 3

    Jinan No. 6 People's Hospital, Department of Neurology, Jinan, Shandong Province, China

*Lan Chu, Department of Neurology, Affiliated Hospital of Guiyang Medical College, No. 28, Gui Yi Street, Guiyang, Guizhou Province, 550004, China. chulan8999@sohu.com.

Publication History

  1. Publication Status: New
  2. Published Online: 30 APR 2013

SEARCH

This is not the most recent version of the article. View current version (06 AUG 2013)

References

Additional references

Aharoni 2012
  • Aharoni R, Saada R, Eilam R, Hayardeny L, Sela M, Arnon R. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 2012;251(1-2):14-24.
Alonso 2008
Barkhof 2009
Brunmark 2002
  • Brunmark C, Runström A, Ohlsson L, Sparre B, Brodin T, Aström M, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 2002;130(1-2):163-72.
Brück 2011
  • Brück W, Wegner C. Insight into the mechanism of laquinimod action. Journal of the Neurological Sciences 2011;306(1-2):173-9.
Brück 2012
  • Brück W, Pförtner R, Pham T, Zhang J, Hayardeny L, Piryatinsky V, et al. Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathology 2012;124(3):411-24.
Cadavid 2009
  • Cadavid D, Cheriyan J, Skurnick J, Lincoln JA, Wolansky LJ, Cook SD. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. Journal of Neurology, Neurosurgery and Psychiatry 2009;80(12):1337-43.
Confavreux 2006
Fernández 2012
  • Fernández Ó, Álvarez-Cermeño JC, Arroyo-González R, Brieva L, Calles-Hernández MC, Casanova-Estruch B, et al. Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I). Revista de Neurologia 2012;54(11):677-91.
Fox 2012
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available from www.cochrane-handbook.org, The Cochrane Collaboration, 2011.
Hulst 2011
Jennum 2012
Karampampa 2012
  • Karampampa K, Gustavsson A, Miltenburger C, Kindundu CM, Selchen DH. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. Journal of Population Therapeutics and Clinical Pharmacology 2012;19(1):e11-25.
Kurtzke 1983
Lidster 2012
Lublin 1996
  • Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11.
McDonald 2001
Mishra 2012
  • Mishra MK, Wang J, Silva C, Mack M, Yong VW. Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. The American Journal of Pathology 2012;181(2):642-51.
Naci 2010
National MS Society 2009
  • National MS Society. Who gets MS?. http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-aboutms/who-gets-ms/index.aspx (accessed 29 November 2012).
Oleen-Burkey 2012
Pike 2012
Polman 2005
Polman 2011
Poser 1983
Review Manager 2011
  • Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration, 2012.
Schulze-Topphoff 2012
  • Schulze-Topphoff U, Shetty A, Varrin-Doyer M, Molnarfi N, Sagan SA, Sobel RA, et al. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLOS One 2012;7(3):e33797.
Shirani 2012
  • Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308(3):247-56.
Thöne 2012
  • Thöne J, Ellrichmann G, Seubert S, Peruga I, Lee DH, Conrad R, et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. American Journal of Pathology 2012;180(1):267-74.
Toubi 2012
  • Toubi E, Nussbaum S, Staun-Ram E, Snir A, Melamed D, Hayardeny L, et al. Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis. Journal of Neuroimmunology 2012;251(1-2):45-54.
Tullman 2004
van den Elskamp 2010
  • van den Elskamp IJ, Boden B, Dattola V, Knol DL, Filippi M, et al. Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis. Neuroradiology 2010;52(10):875-81.
Wegner 2010
  • Wegner C, Stadelmann C, Pförtner R, Raymond E, Feigelson S, Alon R, et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 2010;227(1-2):133-43.
Yang 2004
  • Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. Journal of Neuroimmunology 2004;156(1-2):3-9.
Zivadinov 2012
  • Zivadinov R, Hussein S, Bergsland N, Minagar A, Dwyer MG. Magnetization transfer imaging of acute black holes in patients on glatiramer acetate. Frontiers in Bioscience (Elite Ed) 2012;4:1496-504.
Zou 2002
  • Zou LP, Abbas N, Volkmann I, Nennesmo I, Levi M, Wahren B, et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 2002;42(5):731-9.